Pharmacokinetic Studies of 3-Methyl-1-phenyl-2-pyrazolin-5-one(MCI-186) in rats. (2). Blood and Plasma Levels, Distribution, Metabolism, Excretion and Accumulation during and after Repeated Intravenous Administration.

Preventive effects of edaravone, a free radical scavenger, on lipopolysaccharide‐induced lung injury in mice

“…A sufficient concentration of edaravone for the inhibition of IL‐6 from MH‐S cells ranged from 10–100 µmol/L. At 5 min after a single intravenous administration of edaravone (2 mg/kg/day: roughly equivalent to the daily human dose) to male rats, edaravone levels in plasma and lung tissue were about 1 and 0.5 µmol/L, respectively 15 . To inhibit pro‐inflammatory cytokine production by LPS, concentrations of edaravone 10–100 times higher than the daily human dose might be necessary.…”

“…The main adverse effects of edaravone are renal failure and liver dysfunction 15 . No significant effect on heart rate or blood pressure at the dose of 450 mg/kg of edaravone was reported 16 .…”